Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...

Q4 2024 Management View CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS ...

BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $711.9 million. Product revenues totaled $735.6 million, which rose 16% year over year on higher ...

UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...

Total Revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions. In the quarter, revenues from BioMarin's Enzyme Therapies increased 9% ...

VOXZOGO for achondroplasia experienced 56% year-over-year growth, driven by global expansion and increased penetration in younger pediatric patients. Management also revealed plans to expand ...

Voxzogo continues as a critical driver of revenue growth. The company prioritizes building a robust research and development (R&D) pipeline, advancing scientific innovation, and expanding its ...